As of the latest Form 4 filed Sep 16, 2024.
What Mereo BioPharma Group PLC ADR insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
No Form 4 activity in the trailing 12 months — the table below lists this name’s older filings.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 49 most recent filings for MREO.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-09-16 | 2024-09-13 | Scots-Knight Denise Chief Executive Officer | SSale | −60.0K | $4.22 | $253K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-13 | Lewicki John A. Chief Scientific Officer | SSale | −10.9K | $4.22 | $46.2K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-13 | Sermon Charles General Counsel | SSale | −20.9K | $4.22 | $88.4K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-13 | Fox Christine Ann Chief Financial Officer | SSale | −19.2K | $4.22 | $80.9K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-13 | Hughes-Wilson Alexandra See Remarks | SSale | −84.0K | $4.22 | $355K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-13 | Hughes-Wilson Alexandra, See Remarks | SSale | −16.3K | $4.22 | $68.8K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-12 | Scots-Knight Denise Chief Executive Officer | SSale | −28.6K | $4.47 | $128K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-12 | Lewicki John A. Chief Scientific Officer | SSale | −5.21K | $4.47 | $23.3K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-12 | Sermon Charles General Counsel | SSale | −9.98K | $4.47 | $44.6K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-12 | Fox Christine Ann Chief Financial Officer | SSale | −9.13K | $4.47 | $40.8K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-12 | Hughes-Wilson Alexandra See Remarks | SSale | −40.0K | $4.47 | $179K | No | Form 4 ↗ |
| 2024-09-16 | 2024-09-12 | Hughes-Wilson Alexandra, See Remarks | SSale | −7.77K | $4.47 | $34.7K | No | Form 4 ↗ |
| 2024-09-13 | 2024-09-11 | Sermon Charles General Counsel | MExercise | +65.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-09-13 | 2024-09-11 | Fox Christine Ann Chief Financial Officer | MExercise | +60.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-09-13 | 2024-09-11 | Lewicki John A. Chief Scientific Officer | MExercise | +46.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-09-13 | 2024-09-11 | Scots-Knight Denise Chief Executive Officer | MExercise | +188K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-09-13 | 2024-09-11 | Hughes-Wilson Alexandra See Remarks | MExercise | +75.0K | $1.01 | $75.8K | No | Form 4 ↗ |
| 2024-09-13 | 2024-09-11 | Hughes-Wilson Alexandra, See Remarks | MExercise | +93.3K | $1.40 | $131K | No | Form 4 ↗ |
| 2024-09-13 | 2024-09-11 | Hughes-Wilson Alexandra, See Remarks | MExercise | +40.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-08-23 | 2024-08-22 | PAKIANATHAN DEEPIKA Director | SSale | −105K | $4.43 | $466K | No | Form 4 ↗ |
| 2024-08-23 | 2024-08-22 | PAKIANATHAN DEEPIKA, Director | MExercise | +2.07K | $3.87 | $8.01K | No | Form 4 ↗ |
| 2024-08-23 | 2024-08-22 | PAKIANATHAN DEEPIKA, Director | MExercise | +43.5K | $0.94 | $40.9K | No | Form 4 ↗ |
| 2024-08-23 | 2024-08-22 | PAKIANATHAN DEEPIKA, Director | MExercise | +39.0K | $1.31 | $51.0K | No | Form 4 ↗ |
| 2024-08-23 | 2024-08-22 | PAKIANATHAN DEEPIKA, Director | MExercise | +12.4K | $2.72 | $33.8K | No | Form 4 ↗ |
| 2024-08-23 | 2024-08-22 | PAKIANATHAN DEEPIKA, Director | MExercise | +6.49K | $1.84 | $11.9K | No | Form 4 ↗ |
| 2024-08-23 | 2024-08-22 | PAKIANATHAN DEEPIKA, Director | MExercise | +1.82K | $3.00 | $5.47K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-26 | Sermon Charles General Counsel | SSale | −32.2K | $3.39 | $109K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-26 | Lewicki John A. Chief Scientific Officer | SSale | −16.8K | $3.39 | $57.0K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-26 | Fox Christine Ann Chief Financial Officer | SSale | −29.4K | $3.39 | $99.9K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-26 | Scots-Knight Denise Chief Executive Officer | SSale | −92.3K | $3.39 | $313K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-26 | Hughes-Wilson Alexandra See Remarks | SSale | −23.0K | $3.39 | $77.9K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-25 | Sermon Charles General Counsel | SSale | −14.2K | $3.69 | $52.5K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-25 | Lewicki John A. Chief Scientific Officer | SSale | −7.42K | $3.69 | $27.4K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-25 | Fox Christine Ann Chief Financial Officer | SSale | −13.0K | $3.69 | $48.0K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-25 | Scots-Knight Denise Chief Executive Officer | SSale | −40.7K | $3.69 | $150K | No | Form 4 ↗ |
| 2024-06-27 | 2024-06-25 | Hughes-Wilson Alexandra See Remarks | SSale | −10.1K | $3.69 | $37.4K | No | Form 4 ↗ |
| 2024-06-25 | 2024-06-21 | Lewicki John A. Chief Scientific Officer | MExercise | +69.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-06-25 | 2024-06-21 | Scots-Knight Denise Chief Executive Officer | MExercise | +282K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-06-25 | 2024-06-21 | Sermon Charles General Counsel | MExercise | +98.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-06-25 | 2024-06-21 | Fox Christine Ann Chief Financial Officer | MExercise | +90.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-06-25 | 2024-06-21 | Hughes-Wilson Alexandra See Remarks | MExercise | +60.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-06-17 | 2024-06-17 | WYZGA MICHAEL S Director | AAward | +25.1K | $3.99 | $99.9K | No | Form 4 ↗ |
| 2024-06-17 | 2024-06-17 | Bender Jeremy Director | AAward | +12.6K | $3.99 | $50.1K | No | Form 4 ↗ |
| 2024-05-23 | 2024-05-22 | Hughes-Wilson Alexandra See Remarks | FTax | −24.9K | $1.01 | $25.2K | No | Form 4 ↗ |
| 2024-05-23 | 2024-05-22 | Hughes-Wilson Alexandra, See Remarks | SSale | −50.1K | $2.94 | $147K | No | Form 4 ↗ |
| 2024-05-23 | 2024-05-22 | Hughes-Wilson Alexandra, See Remarks | MExercise | +75.0K | $1.01 | $75.8K | No | Form 4 ↗ |
| 2024-05-23 | 2024-05-22 | Hughes-Wilson Alexandra, See Remarks | FTax | −43.0K | $1.40 | $60.2K | No | Form 4 ↗ |
| 2024-05-23 | 2024-05-22 | Hughes-Wilson Alexandra, See Remarks | SSale | −50.4K | $2.99 | $151K | No | Form 4 ↗ |
| 2024-05-23 | 2024-05-22 | Hughes-Wilson Alexandra, See Remarks | MExercise | +93.3K | $1.40 | $131K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also MREO’s full analysis or the market-wide insider trading feed. The tabs above jump to MREO’s other SEC data.
Source: SEC Form 4 filings for MREO, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.